Allergen-specific immunotherapy with Der p 1/2 mRNA vaccines alleviates house dust mite-induced allergic airway inflammation in a mouse model

🥈 Top 2% JournalJan 4, 2026Molecular therapy : the journal of the American Society of Gene Therapy

mRNA Vaccines Targeting Dust Mite Allergens Reduce Allergic Airway Inflammation in Mice

AI simplified

mRNA Technology on OpenScience ↗PubMed ↗DOI ↗

Abstract

LNP-mRNA vaccines encoding Der p 1 and Der p 2 increased Der p 1/2-specific IgG1 and IgG2a titers by more than 10-fold.

LNP-mRNA vaccines triggered strong humoral immunity and showed good tolerability in a mouse model.
Subcutaneous immunotherapy reduced early allergic responses, airway hyperresponsiveness, eosinophil infiltration, and mucus hypersecretion.
LNP-mRNA vaccines were more effective than HDM extract in suppressing Th2-driven inflammation and decreasing total and HDM-specific IgE levels.
The vaccines enhanced regulatory T cell populations and restored the balance between Th1 and Th2 cells, resulting in an approximately 2-fold increase in Th1 cells.
Elevated frequencies of certain immune cells, including cDC1, cDC2, and pDC, indicated innate immune activation.

AI simplified

Allergen-specific immunotherapy (AIT) is the only disease-modifying treatment for allergic diseases, but current crude-extract-based approaches suffer from poor standardization and variable safety and efficacy. This study developed lipid nanoparticle (LNP)-encapsulated mRNA vaccines encoding Der p 1 and Der p 2, the major house dust mite (HDM) allergens, and evaluated them in a murine model of HDM-induced airway inflammation. LNP-mRNA vaccines triggered potent humoral immunity and exhibited good tolerability. Subcutaneous immunotherapy significantly reduced early allergic responses, airway hyperresponsiveness, eosinophil infiltration, and mucus hypersecretion. Compared with HDM extract, LNP-mRNA more effectively suppressed T helper cell 2 (Th2)-driven inflammation, decreased total and HDM-specific IgE, and induced allergen-specific blocking antibodies. Specifically, Der p 1/2-specific IgG1 and IgG2a titers increased by more than 10-fold, markedly inhibiting basophil activation. Mechanistically, LNP-mRNA enhanced regulatory T cell (Treg) and type 1 Treg (Tr1) populations, restored Th1/Th2 balance with an approximately 2-fold increase in Th1 cells, reduced innate lymphoid cell 2 (ILC2) frequencies, and promoted germinal center B and T follicular helper responses. Innate immune activation was also observed, with elevated dendritic cells type 1 (cDC1), dendritic cells type 2 (cDC2), and plasmacytoid dendritic cells (pDC) frequencies. These results demonstrate that HDM LNP-mRNA vaccines are safe, are immunologically potent, and represent a standardized next-generation approach for AIT.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Featured in

mRNA TechnologyIssue #1pro

Scientists can now watch mRNA vaccines travel through the body in real-time using fluorinated nanoparticles

↗

Abstract

Full Text

Related papers

Featured in